UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

Benzinga · 2d ago
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.